Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kaken Pharmaceutical CoKKPCF 69 PE Ratio (TTM) is 70.08 as of Jul. 21, 2026, which is 452% above its 10-year median of 12.69. GuruFocus rates KKPCF with a GF Score™ of 69/100 and a GF Value™ of $25.42. The stock has 2 warning signs investors should review. Among 639 Drug Manufacturers companies, Kaken Pharmaceutical Co ranks worse than 85.6% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-21), Kaken Pharmaceutical Co's share price is
$26.00.
Kaken Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.37. Therefore, Kaken Pharmaceutical Co's PE Ratio (TTM) for today is 70.08.
The historical rank and industry rank for Kaken Pharmaceutical Co's PE Ratio (TTM) or its related term are showing as below:
KKPCF'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 7.79 Med: 12.69 Max: 287.46
Current: 68.23
During the past 13 years, the highest PE Ratio (TTM) of Kaken Pharmaceutical Co was 287.46. The lowest was 7.79. And the median was 12.69.
KKPCF's PE Ratio (TTM) is ranked worse than 85.6% of 639
companies
in the Drug Manufacturers industry
Industry Median: 21.04
vs KKPCF: 68.23
During the past 13 years, Kaken Pharmaceutical Co's highest 3-Year average EPS without NRI Growth Rate was 35.10% per year. The lowest was -28.20% per year. And the median was 5.55% per year.
Kaken Pharmaceutical Co (OTCPK:KKPCF) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Kaken Pharmaceutical Co PE Ratio (TTM) Related Terms
Kaken Pharmaceutical Co PE Ratio (TTM) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaken Pharmaceutical Co PE Ratio (TTM) vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Kaken Pharmaceutical Co's PE Ratio (TTM) falls into.
Kaken Pharmaceutical Co PE Ratio (TTM) Calculation
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Kaken Pharmaceutical Co's Share Price of today is $26.00.
Kaken Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.37.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Kaken Pharmaceutical Co (KKPCF) has a PE Ratio (TTM) of 70.08 as of Jul. 21, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Kaken Pharmaceutical Co and its competitors. This is 452% above median its historical median of 12.69. Over the past decade, Kaken Pharmaceutical Co's PE Ratio (TTM) has ranged from 7.79 to 287.46. According to the industry distribution chart, Kaken Pharmaceutical Co ranks #547 out of 639 companies in the Drug Manufacturers industry, placing it in the top 85.6%.
Is Kaken Pharmaceutical Co's PE Ratio (TTM) too high?
Kaken Pharmaceutical Co's current PE Ratio (TTM) of 70.08 is 452% above median its 10-year median of 12.69. Over the past 10 years, this metric has ranged from a low of 7.79 to a high of 287.46. The Drug Manufacturers industry median PE Ratio (TTM) is 21.04. Kaken Pharmaceutical Co's value of 70.08 is 233.1% above this industry median. Based on the distribution chart, Kaken Pharmaceutical Co ranks #547 out of 639 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Kaken Pharmaceutical Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's PE Ratio (TTM) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kaken Pharmaceutical Co ranks #547 out of 639 companies for PE Ratio (TTM). This places Kaken Pharmaceutical Co in the lower half of its industry. The industry median PE Ratio (TTM) is 21.04. Kaken Pharmaceutical Co's value of 70.08 is 233.1% above this benchmark. Historically, Kaken Pharmaceutical Co's own PE Ratio (TTM) has ranged from 7.79 to 287.46 over the past decade. While the company's 10-year median is 12.69 vs. the industry median of 21.04, Kaken Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Drug Manufacturers company?
The median PE Ratio (TTM) among Drug Manufacturers companies is 21.04, based on 639 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kaken Pharmaceutical Co's current PE Ratio (TTM) of 70.08 is 233.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Kaken Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PE Ratio (TTM) is 21.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaken Pharmaceutical Co's current PE Ratio (TTM) is 70.08, which is 452% above median its own 10-year median of 12.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Kaken Pharmaceutical Co (KKPCF) has a current PE Ratio (TTM) of 70.08. The stock's GF Value™ is $25.42, compared to a current price of $26.00 — trading 2.3% above its estimated fair value. The current PE Ratio (TTM) is 70.08, which is 452% above median its 10-year median of 12.69 and 233.1% above the Drug Manufacturers industry median of 21.04. Kaken Pharmaceutical Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Kaken Pharmaceutical Co (KKPCF), the current PE Ratio (TTM) is 70.08 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kaken Pharmaceutical Co (KKPCF) Overvalued in 2026?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be overvalued.
The current stock price of $26.00 is trading 2.3% above its estimated GF Value™ of $25.42.
Key valuation signals for KKPCF:
PE Ratio (TTM): 70.08 (452% above median its 10-year median of 12.69)
GF Value™: $25.42 vs. price of $26.00 (2.3% above fair value)
Industry Position: 233.1% above the Drug Manufacturers median (#547 of 639)
No single metric tells the full story. See the KKPCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
69GF Score
Get the complete analysis for KKPCF
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KKPCF has been successfully added to your 
